Ibandronate Sodium Injection
Product Images NDC 60505-6097

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Ibandronate Sodium (NDC 60505-6097). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ibandronate 01)

This text appears to be discussing two different dosage options for increasing Lumbar Spine BMD (bone mineral density) and their effectiveness. The first option is a daily 2.5mg dose, while the second option is a 3mg dose given once every three months either orally or intravenously. The study mentioned compared the two dosages and found that the 3mg every 3 months was more effective, with a statistically significant difference (p<0.001).*

FDA Label Image

Figures 2 (Ibandronate 02)

FDA Label Image

Ibandronate-04 (Ibandronate 04)

FDA Label Image

Ibandronate-05 (Ibandronate 05)

Ibandronate Sodium Injection is a sterile, single-use, prefilled syringe with a quantity of 3 mg*/3 mL (1 mg/mL), to be used intravenously only. It contains Ibandronate sodium monohydrate, equivalent to 3 mg ibandronate free acid. It is accompanied by prescribing information and should be stored at temperatures between 15°C-30°C (59°F-86°F). Unused portions of the solution should be discarded. It is manufactured in India by Gland Pharma Limited and distributed by Apotex Corp. in Weston, Florida.*

FDA Label Image

Chemical Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.